Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
White Papers / Tech Papers Tackling Poor Bioavailability with Early Formulation Strategies De-risking oral clinical development with UpperSolv Released By Upperton High failure rates in clinical trials, estimated at up to 90%, remain a major hurdle in drug development, with poor ADME (Absorption, Distribution, Metabolism, and Excretion) properties being one of the leading causes of late-stage attrition
special focus on central nervous system imaging
300 PI3K exerts effects through the Akt/PKB and protein kinase C cascades, 300 with Akt activation inhibiting GSK3 via mTOR and downstream elements, promoting glycogen synthesis
Patients can lose 10% to 18% of their body weight and 20% to 25% with some of the newer medications, according to Dr
der Pol YV , Yilma B, Morris VK, Chao C, Harris M, Guinney J, Kopetz S
US$ 25.36
US$ 21.83
US$ 28.17
US$ 27.10
US$ 28.13
US$ 21.02
US$ 24.61
US$ 27.22
US$ 20.43
US$ 28.05
